Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of ZG006 versus investigator's choice chemotherapy in advanced neuroendocrine carcinoma
CTR20261891Phase 3Active
- Sponsor
- Zelgen
- Start
- Jul 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of alveltamig in neuroendocrine carcinoma (NEC), sponsored by Zelgen. Started Jul 2026; status: active.
02
Drugs
alveltamig
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on CTR20261891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261891.